The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 72 (high attention) · dilution pressure high · listing risk elevated · governance risk low · runway 21.3 mo · strongest signal: PIPE (Sep 16, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (negative equity) coexists with live selling machinery (pipe, shelf filed). Base case is a discounted raise; the question is when, not if.
On August 21, 2026, Adial Pharmaceuticals disclosed in an 8-K (Item 3.01) that it received a Nasdaq delisting notice for failing both the $5 million Minimum Value of Listed Securities (MVLS) standard and the stockholders' equity standard. The company had $28.7 million cash and negative $38.4 million equity as of June 30, 2026, implying approximately 21 months of runway. Reverse-split proposals appeared in preliminary and definitive proxy materials filed August 11 and August 24, and a shelf registration (S-3) was filed August 28.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 84 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Sep 18, 2026 | ▼ Reverse split | “reverse split” language in 8-K (EX-10.2) filed 2026-09-18 filing | 35 |
| Sep 18, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-09-18 (accepted 16:27 ET) filing | 24 |
| Sep 16, 2026 | ▼ PIPE | “pipe” language in 8-K (EX-10.1) filed 2026-09-16 filing | 38 |
| Aug 28, 2026 | ▼ Shelf filed | S-3 filed 2026-08-28 filing | 35 |
| Aug 25, 2026 | ▼ Unregistered sale | 8-K Item 3.02 filed 2026-08-25 (accepted 16:33 ET) filing | 34 |
| Aug 24, 2026 | ▼ Reverse split | “reverse split” language in DEF 14A (DEF 14A) filed 2026-08-24 filing | 30 |
| Jun 30, 2026 | ▼ Negative equity | Stockholders' equity $-38,377,000 as of 2026-06-30 filing | 31 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $6,483,200 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 24 |
SDST Stardust Power Inc. · GOVX GeoVax Labs, Inc. · MYSZ My Size, Inc. · SNTI Senti Biosciences Holdings, · GCTK Glucotrack, Inc. · SOAR Volato Group, Inc. · screener →